This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.
All eligible consenting patients will undergo daily stoma management per standard of care.
Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.
Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.
Follow-up: Study participants will be followed at 1 week and 2 weeks.

开始日期2026-10-01

申办/合作机构

Dartmouth-Hitchcock Medical Center

[+1]

NCT06876038

/ Not yet recruiting临床2期IIT

A Comprehensive Platform for Low-cost Screening and Image-guided Photodynamic Therapy (PDT) Treatment of Pre-malignant and Malignant Oral Lesions in Low-resource Setting

The primary goal of this study is to see if photodynamic therapy (PDT) is effective for treatment of lesions in the oral cavity which have high risk of becoming oral cancer. PDT treatment uses a drug, called a photosensitizer, which makes the diseased cells become light-sensitive such that they are destroyed when laser light is delivered to the target lesion. In this study a new handheld device, called SITOS (a "Screen, Image and Treat Optical System), is used. The ability of this device to simultaneously visualize the inside of the mouth and deliver laser light to the target site will be evaluated. The main questions this study seeks to answer are:
* Can this treatment completely cure oral potentially malignant lesions (OPML) without need for surgery?
* Do lesions recur after PDT treatment?
* Is the SITOS device easy to use for the doctor and comfortable for the patient, both as an oral imaging device and as a treatment device?

开始日期2026-09-01

申办/合作机构

University of Massachusetts Boston

[+4]

NCT07038278

/ Not yet recruiting早期临床1期IIT

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (5-ALARMS)

The goal of this study is to learn if the intervention using a fluorescent agent 5-Aminolevulinic acid (5-ALA) to aid in the surgical approach to visualize the soft-tissue sarcoma (STS) during surgical resection. 5-ALA goes through the blood stream and into the tumor tissue allowing it to light up when the surgeon uses a special light in the operating room. The technique is called 5-ALA fluorescence-guided surgery (FGS). The main question aims to answer if 5-ALA provide intraoperative fluorescent visualization of soft-tissue sarcoma versus surrounding tissue and demonstrate the efficacy of tumor and surgical margin resections by a gross and histological analysis of fluorescing and non-fluorescing samples immediately after removal. Participants will be asked to orally administer 5-ALA three to four hours prior to surgery in preoperative area.

开始日期2026-09-01

申办/合作机构

University of Colorado Denver

100 项与盐酸氨酮戊酸相关的临床结果

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的转化医学

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的专利（医药）

登录后查看更多信息

7,309

项与盐酸氨酮戊酸相关的文献（医药）

2026-12-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Evaluating the global cellular pharmacological effects of photodynamic therapy using label-free surface-enhanced Raman spectroscopy

Article

作者: Lu, Feng ; Yuan, Yongfang ; Wang, Shiwei ; Zhu, Qingxia ; Zhou, Qing

Photodynamic therapy (PDT) has attracted widespread attention as an emerging cancer treatment, yet real-time monitoring of tumor oxidative stress during therapy remains challenging due to unclear mechanistic insights, delayed efficacy evaluation, and inefficient drug screening. This study employed label-free dynamic surface-enhanced Raman spectroscopy (D-SERS) to evaluate the cellular pharmacological effects of PDT, enabling the mechanism-based classification of agents. Label-free D-SERS was used to monitor real-time spectral changes in human melanoma cells during PDT, characterizing the differences between apoptosis-inducing (type A) and necrosis-inducing (type B) photosensitizers. Type A exhibited concentration-dependent increases in Raman peaks at 652, 742, 828, and 1000 cm^-1, a trend absent in Type B. By analyzing DNA, lipid, and amino acid peak ratios, cells treated with these photosensitizers were clearly classified into two mechanistic groups (A and B). Furthermore, D-SERS was applied to study the Type B agent 5-ALA in combination with heme oxygenase-1 (HO-1) modulators, verifying the associated enzyme-regulatory processes. This study presents a proof-of-concept model for the spectral mechanism-based screening of photosensitizers and enzyme modulators, thus aiding the optimization of PDT efficacy and targeted drug development.

2026-09-01·MICROBIAL PATHOGENESIS

Synergistic inactivation of Micrococcus luteus and its biofilms by 5-aminolevulinic acid-mediated photodynamic therapy

Article

作者: Wang, Chao ; Mai, Yuxiu ; Yu, Jianyu ; Wang, Zhaodan ; Xu, Shulan

BACKGROUND:

Micrococcus luteus is an opportunistic nosocomial bacterial species with the ability to form biofilms on medical devices, and the emergence of antibiotic tolerance in M. luteus necessitates the development of alternative therapeutic strategies. 5-Aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) represents a promising alternative, leveraging the bacterial endogenous heme biosynthetic pathway to generate cytotoxic reactive oxygen species upon light activation.

METHODS:

The intrinsic heme biosynthesis pathway of M. luteus was utilized for photosensitizer production. Bacterial cells and 4-day mature biofilms formed on titanium surfaces were incubated with varying concentrations of 5-ALA (0-0.5%) and subsequently irradiated using a 405 nm LED light source at fluences of up to 27 J/cm². Porphyrin accumulation was quantified by fluorescence spectroscopy. The antibacterial and anti-biofilm efficacies of ALA-PDT were systematically evaluated using colony-forming unit (CFU) counts, live/dead staining, fluorescence microscopy, and scanning electron microscopy (SEM).

RESULTS:

Fluorescence spectroscopy revealed that treatment with 0.1% (w/v) 5-ALA for 2 h resulted in maximum porphyrin accumulation. When combined with light irradiation at 18 J/cm², this protocol achieved significant, concentration- and time-dependent killing of planktonic M. luteus, with no observed dark toxicity. CFU counts indicated that this optimized ALA-PDT protocol also effectively eradicated mature biofilms on titanium, leading to a substantial reduction in viable bacterial counts. Notably, the combination of 5-ALA and light exhibited superior bactericidal activity compared to either treatment alone, confirming the synergistic nature of this therapeutic approach. Fluorescence microscopy and SEM consistently revealed that ALA-PDT not only killed embedded bacteria but also disrupted the extracellular matrix and reduced biofilm thickness, whereas 5-ALA alone or light alone only diminished intercellular connections without causing cell death.

CONCLUSIONS:

This study demonstrates that ALA-PDT is a highly effective approach for eliminating both planktonic and biofilm-associated M. luteus. The synergistic combination of 5-ALA and light irradiation achieves both bacterial killing and biofilm disruption. Our findings underscore the potential of ALA-PDT as a non-antibiotic strategy for managing infections caused by this resilient pathogen, especially those related to medical implants.

2026-09-01·Bioactive Materials

Intelligent microneedle patch with cobalt-iron Prussian blue nanozymes for accelerating diabetic wound healing via heme biosynthesis-driven immunomodulation

Article

作者: Kuang, Yichen ; Zhu, Yutong ; Ning, Mingliang ; Chen, Hangrong ; Miao, Runjie

A complex wound microenvironment with the presence of bacterial infection, overproduction of hydrogen peroxide (H₂O₂), chronic inflammation, poor vascularization and hypoxia wound result in delayed healing of diabetic wounds. In this study, a novel antibacterial microneedle patch integrating cobalt-iron Prussian blue (CFP) nanoenzymes loaded with prodrug 5-aminolevulinic acid (5-ALA) for intelligent, multi-stage therapeutic intervention on diabetic infected wound healing. Specifically, ALA@CFP demonstrated peroxidase (POD)-like activity to initiate the in situ production of hydroxyl radicals in response to elevated H₂O₂ in the wound, which proficiently induced bacterial ferroptosis and dismantled the bacterial biofilms, while the catalase (CAT)-like activity alleviated hypoxia wound conditions via decomposing H₂O₂ to produce oxygen. Simultaneously, Fe²⁺ released from ALA@CFP facilitated the transformation of 5-ALA to heme, significantly amplifying downstream heme oxygenase-1 (HO-1) activity and producing endogenous anti-inflammatory mediators, carbon monoxide and bilirubin. These molecules subsequently restructured the inflammatory wound microenvironment by instigating the polarization of macrophages from the M1-phenotype to the pro-repair M2-phenotype and upregulated the expression of anti-inflammatory factors, thereby fostering cell migration and angiogenesis. When embedded in a methacrylated gelatin/carboxymethyl chitosan hydrogel microneedle matrix, the system enables on-demand deep tissue delivery, achieving simultaneous antibacterial, anti-inflammatory, pro-angiogenic and regenerative effects in an infected diabetic mouse model. This study demonstrates a material-driven, metabolism-amplified strategy for intelligent wound repair, providing a promising platform for next-generation functional biomaterials.

194

项与盐酸氨酮戊酸相关的新闻（医药）

2026-08-05

·BioSpace

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED ® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026. Management will host a conference call and webcast the same day at 10:00 a.m. Eastern Time to discuss the results and provide a business update. Conference Call and Webcast Details Detail Information Date Thursday, August 13, 2026 Time 10:00 a.m. Eastern Time U.S. / Canada toll-free 1-877-877-1275 International 1-412-858-5202 Webcast Participants dialing in by telephone should ask to be joined into the Biofrontera call. The webcast will be accessible beginning approximately 20 minutes prior to the start of the call. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); About Biofrontera Inc. Biofrontera Inc. (NASDAQ: BFRI) is a U.S. specialty dermatology company focused on the treatment of dermatological conditions. The Company commercializes Ameluz ® (aminolevulinic acid hydrochloride) Gel, 10%, together with the BF-RhodoLED ® lamp, for photodynamic therapy (PDT) in the treatment of actinic keratosis. Biofrontera Inc. has been a standalone, publicly traded company since its 2021 IPO and operates a wholly owned subsidiary, Biofrontera Discovery GmbH, in Germany. For more information, visit . Investor Contact Ben Shamsian Lytham Partners shamsian@lythampartners.com

财报

2026-07-27

·乐药投资

已完成数十例IIT用于痤疮等多种皮肤疾病创新光敏药物研发企业股权融资（QY436）

基本信息临床现状：艾拉（盐酸氨酮戊酸散）是国内2007年获批的外用光动力光敏剂，被多个指南共识推荐用于尖锐湿疣、皮肤囊肿痤疮等，治疗效果好、复发率低，每年销售数亿元。但治疗过程有明显的局部疼痛、肿胀，患者依从性不佳，且必须配套光动力治疗仪在院内治疗，限制了产品市场空间。项目优势：本产品是一种新型的光动力药物，无需配套光动力治疗仪，自购几百元LED灯即可居家治疗。本产品显著抑制了发光、发热，提升了光动力性能和治疗效果，使用剂量低且几乎无痛感，已探索多个适应症，市场空间大。研究进展：对于中重度痤疮、病毒疣、脚气，以及面部除皱、纹理改善等做了数十例IIT试验，治疗效果明显。融资情况：本轮为公司首轮融资，计划融资2000万元，用于完成核心管线临床前研究、提交IND申请并获得批件。项目联系联系我们：南京市建邺区庐山路288号升龙汇金中心4栋505室 Room 505, Building 4, Shenglonghuijin Center, No.288 Lushan Road, Jianye, Nanjing 合作咨询 jlzhou@loveyao.cn 周先生 18252050686（微信同号）一家专注于生物医药行业高度整合项目、资源、资本、人才及智力链条的专业投资并购经纪平台。平台合伙人分别在医药、金融、财法务等领域具有深厚功底和实操经验，在项目实操中能够提供完整的信息调研、交易架构设计、估值模型搭建、尽职调查、风险控制、税务筹划等专业的服务和方案。平台项目库现储备有一千多个候选项目，覆盖了化药、中成药、创新药、IVD、高端器械及细胞基因疗法等近90%的医药行业次级领域，在医药行业有比较好的口碑和地位，是您投资、并购及BD事业上的专业合作伙伴！（封面及配图由ai生成）

2026-06-27

·Drug科技与狠活

研发动向分析第八期

重点专利深度分析报告 Differentiation Platform · FIC/BIC Molecules · MNC Intelligence 2026年6月27日· Cortellis专利数据库· EPO Espacenet验证 798篇分析总量 12篇重点分析 7篇 MNC专利 4家中国创新公司 5个差异化平台一、执行摘要本报告从798篇Cortellis公开专利中，通过五维评分模型（MNC权重+ 中国公司创新力+ FIC/BIC潜力+ 平台差异化+ 投融资背景）筛选出12篇重点专利，涵盖MNC战略布局、中国创新公司崛起、国际学术合作三大叙事线。核心发现：Roche/Genentech展现出在基因治疗（AAV）和RNA递送（LNP）领域的核心技术平台化布局；中国公司从fast-follow转向差异化平台创新（GeneQuantum ADC高通量筛选、Fosun Kairos CAR-T新适应症、WuXi Biologics免疫分析平台）；国际学术界贡献了FIC分子和工具平台（IAVI/Scripps HIV疫苗、Harvard电化学传感、CAS TCR工程改造）。二、重点专利概览矩阵优先级专利号申请人靶点/技术标签总分 P1 WO2026124560 GeneQuantum（启德医药） ADC高通量筛选平台差异化平台/ 中国公司 12 P1 WO2026125556 Sanofi SA tolC/fhuA噬菌体抗性 MNC 11 P1 WO2026128686 Genentech（Roche） LNP脂质/核酸同时定量 MNC / 平台工具 11 P1 WO2026119948 Roche AAV组织分布检测 MNC / 平台工具 11 P2 WO2026119250 Fosun Kairos（复星凯瑞） BCMA-CD19双靶CAR-T FIC / 中国公司 10 P2 WO2026123778 WuXi Biologics（药明生物）免疫激活报告细胞系平台/ 中国公司 10 P2 WO2026125718 Cue Biopharma+ImmunoSCAPE WT-1靶向TCR FIC / 国际合作 10 P2 WO2026122414 Genentech（Roche） nanoMAPS细胞表面蛋白组学 MNC / 平台工具 11 P2 WO2026122534 IAVI+Scripps Research HIV Apex bnAb免疫原 FIC / 学术前沿 10 P3 WO2026125666 Roche 虫媒病毒多重PCR MNC / 诊断 11 P3 WO2026122663 Harvard University 电化学竞争免疫分析学术平台 10 P3 WO2026114238 中科院分子细胞卓越中心 MAGE-A3 TCR工程改造中国学术/ FIC 10 三、MNC专利深度分析 3.1 Roche/Genentech —基因与RNA治疗核心技术平台 [MNC · Roche] [差异化平台] WO2026119948 AAV颗粒组织分布检测技术公布: 2026-06-11 · 优先权: 2024-12-05 申请人 F. Hoffmann-La Roche Ltd IPC C07K14/005; C12N15/86 发明人 Edelmann MR, Fakhiri J 等技术 AAV基因治疗· ¹⁴C标记· 组织分布 🔬 技术机制使用¹⁴C放射性同位素标记AAV衣壳蛋白，通过定量全身放射自显影精确定量AAV在各组织中的分布。进一步筛选针对特定组织的AAV衣壳变体。 ⭐ 差异化价值精确定量AAV组织分布是基因治疗载体设计的核心瓶颈。Roche通过¹⁴C标记→体内分布→衣壳筛选完整闭环，系统性解决AAV递送效率问题。战略背景：2024年10月与Dyno Therapeutics达成超$10亿合作，利用AI设计新一代AAV衣壳（神经疾病方向），2025年初已行使首个神经基因治疗衣壳授权。本专利为该合作提供技术支撑。 💡 战略判断 Roche在AAV领域三大支柱：Spark Therapeutics收购（商业化）+ Dyno AI衣壳（技术迭代）+ 本组织分布检测（研发工具）。完整闭环使Roche在下一代AAV竞争中占据优势。 [MNC · Genentech] [差异化平台] WO2026128686 LNP制剂脂质/核酸成分同时定量方法公布: 2026-06-18 · 优先权: 2024-12-13 申请人 Genentech Inc IPC G01N30/34; G01N30/88 发明人 Chen Tao, Fan Yuchen, Su Wan-Chih 技术 IPRP-HPLC + UV + CAD检测 🔬 技术机制采用离子对反相高效液相色谱（IPRP-HPLC）同时分离LNP制剂中多种脂质成分和核酸载药，结合UV和CAD检测，单次色谱运行即可完成多成分同时定量。此前Genentech已提交WO2026076250（CNS靶向LNP），本分析技术是其LNP平台的必要配套工具。 ⭐ 差异化价值 LNP制剂中不同脂质和核酸的独立定量是质量控制痛点。传统方法需多次独立分析，本专利实现单次运行全组分定量，支持LNP从研发到生产的全过程控制。 [MNC · Genentech] [差异化平台] WO2026122414 nanoMAPS纳米磁亲和纯化细胞表面蛋白组学公布: 2026-06-11 · 优先权: 2024-12-04 申请人 Genentech Inc 适应症 IBD/结肠炎技术生物素标记+ 磁珠纯化+ 质谱应用 IBD血浆细胞表面标志物发现 🔬 技术机制 nanoMAPS平台：少量细胞→生物素化学标记→抗生蛋白链菌素偶联磁珠捕获→质谱驱动蛋白组学分析。克服传统方法需大量细胞的限制，可对微量临床样本（如IBD活检）进行高通量分析。 ⭐ 差异化价值 nanoMAPS填补了微量细胞表面蛋白组学分析的技术空白，整合PTMScan®自动化能力，形成从biomarker发现到靶点验证的完整链路。 3.2 Sanofi —生物制造技术创新 [MNC · Sanofi] WO2026125556 tolC/fhuA基因修饰噬菌体抗性菌株公布: 2026-06-18 · 优先权: 2024-12-12 申请人 Sanofi SA 靶向基因 tolC + fhuA双基因修饰适应症生物制造抗噬菌体污染噬菌体谱 TLS, T1, T5噬菌体 🔬 技术机制 tolC蛋白是TLS/T1/T5噬菌体的细胞表面受体。定点突变tolC蛋白S279-N304区域阻断噬菌体吸附。fhuA基因额外修饰提供协同抗性。菌株维持正常蛋白表达功能。 ⭐ 商业化意义噬菌体污染是生物制药发酵生产的重大痛点（单次污染可造成数百万美元损失）。Sanofi通过基因工程从根源解决问题，也可向其他CMO/CDMO授权。 3.3 Roche —分子诊断平台扩展 [MNC · Roche] WO2026125666 虫媒病毒多重PCR检测方法公布: 2026-06-18 · 优先权: 2024-12-11 申请人 Roche / Roche Molecular Systems 技术平台多重PCR · cobas®系统场景虫媒病毒：登革热/Zika/基孔肯雅等 💡 战略判断 Roche在分子诊断领域拥有cobas®平台的深厚积累。本专利扩展其多重病原体检测能力，与同期WO2026128440（串联等温扩增+PCR）和WO2026125536（基因组分析）形成完整方案。四、中国公司创新能力分析 [中国公司] [差异化平台] WO2026124560【最高分12分】 GeneQuantum（启德医药）— 生物偶联药物高通量制备筛选系统公布: 2026-06-18 · 优先权: 2024-12-11 申请人 GeneQuantum Healthcare / GeneQuantum Medicine (Suzhou) IPC A61K31/5365; A61K47/54,68 发明人 Qin Gang, Zhang Hongwei 等10人领域 ADC · 高通量筛选· 平台 🔬 技术机制— 四步级联筛选体系 Step1 高通量制备→ 生物偶联库A; Step2 细胞/类器官初筛→ 偶联库B; Step3 患者来源PDX动物模型二筛→ 偶联库C; Step4 药理/毒理研究→ 临床前候选化合物。 ⭐ 差异化平台分析 GeneQuantum已建立iLDC和iGDC双平台，2023年与Nona Biosciences（Harbour Mice）达成独家合作。四步高通量筛选系统是其ADC平台的系统化延伸。相比国际ADC公司通常依赖低通量筛选，高通量方法有望加速临床前候选药物发现。 💰 投融资背景启德医药完成多轮融资，投资方包括中国人寿PE（领投）、PICC资本、Huagai Capital、三生国健等8家机构。2025年1月与Biohaven等美国公司达成总价值$13亿ADC合作协议。 [FIC潜力] [中国公司] WO2026119250 BCMA-CD19双特异性CAR-T治疗淀粉样变性公布: 2026-04-14 · 优先权: 2024-12-05 申请人 Shanghai Fosun Kairos Biotechnology 先导产品 FKC-289（Fosunova-T平台）适应症 AL淀粉样变性· 膜性肾病临床状态 IND批准（2026年1月） 🔬 FIC机制分析 FKC-289是全球首款BCMA-CD19双靶自体CAR-T用于非肿瘤适应症。通过同时靶向BCMA（浆细胞）和CD19（B细胞）实现致病细胞双重深度耗竭，抑制单克隆免疫球蛋白轻链及错误折叠蛋白沉积。2026年5月初步临床数据积极。 ⭐ 差异化与风险 FIC论证：CAR-T从肿瘤拓展到非肿瘤自身免疫/蛋白沉积疾病。2026年6月MN/ALA双适应症获批临床。风险：CAR-T在非肿瘤适应症的安全性（CRS、神经毒性）和成本效益仍需验证。 [差异化平台] [中国公司] WO2026123778 高性能免疫激活报告细胞系公布: 2026-06-18 · 优先权: 2024-12-13 申请人 WuXi Biologics (Shanghai) 平台 TATA盒/最小IL-2启动子驱动应用免疫调节剂筛选· 效力检测药物 blinatumomab / rituximab / lulizumab 🔬 技术机制利用IL-2调控元件（AP-1/CD28 RE或NFAT/AP-1/Oct-1/EGR1 RE）连接TATA盒/最小IL-2启动子，避免特定转录因子触发的反应偏差，实现信号增强的生物测定性能。 ⭐ 商业化模式 WuXi Biologics作为全球Top CDMO，该技术以内化使用提升生物测定服务能力，同时可作为report gene assay服务对外提供，在单抗/双特异性抗体效力检测中具有标准化价值。五、国际学术合作与创新 [FIC分子] [国际学术合作] WO2026122534 ApexGT6 HIV广谱中和抗体免疫原· mRNA/LNP 公布: 2026-06-11 · 优先权: 2024-12-02 申请人 IAVI + Scripps Research Institute 核心分子 ApexGT6 工程化HIV Env三聚体递送佐剂蛋白/ mRNA-LNP 合作 Moderna (mRNA-1574, Phase 1) 🔬 科学背景 ApexGT6是工程化HIV Env三聚体，专门设计激活前体B细胞产生靶向HIV Env Apex表位的bnAbs。在非人灵长类中已成功诱导bnAb前体B细胞。 ⭐ 差异化价值 2025年5月IAVI/Scripps在Science发表两篇Phase 1 HIV疫苗试验，首次在人体证明胚系靶向策略可激活bnAb前体。本专利ApexGT6从proof-of-concept进入优化免疫原设计阶段。Moderna mRNA-1574是将该免疫原以mRNA-LNP递送的产业化尝试。 💰 战略投资 IAVI由Gates Foundation、USAID/PEPFAR等资助。Scripps的William Schief教授是HIV胚系靶向先导。Moderna投入HIV mRNA平台。Amgen Ventures和EDBi支持ImmunoSCAPE的TCR发现平台，形成"疫苗+TCR"双通道。 [FIC潜力] [国际合作] WO2026125718 WT-1靶向TCR-T细胞受体公布: 2026-06-18 · 优先权: 2024-12-13 申请人 Cue Biopharma (NASDAQ:CUE)+ImmunoSCAPE 靶点 WT-1 · HLA-A*02:01限制性平台 Deep Immunomics + Immuno-STAT 🔬 技术机制提供特异性结合WT-1衍生肽的TCR序列（CDR1α-3α, CDR1β-3β全定义）。WT-1是肿瘤-睾丸抗原，在AML、胶质母细胞瘤等过表达。Immuno-STAT平台设计与WT-1 TCR匹配的T细胞接合器，形成Seed-and-Boost策略。 💰 合作背景 2025年11月Cue Biopharma（NASDAQ:CUE, 市值~$5600万）与ImmunoSCAPE（A*STAR孵化，Amgen Ventures/EDBi投资）宣布战略合作。代表小型biotech通过技术互补降低开发风险的新范式。 [学术创新] [平台工具] WO2026122663 电化学竞争免疫分析系统公布: 2026-06-11 · 优先权: 2024-12-04 申请人 Harvard University · Wyss Institute 发明人 Donald Ingber, Jolly Pawan 等授权方 StataDX 检测 Cortisol · Testosterone ⭐ 技术亮点独特正相关电化学输出竞争免疫分析设计：目标捕获→目标功能化电极结合→绝缘沉淀→电流测量。将传统竞争法反向信号转为正向读出，提升定量准确性。 Donald Ingber（Wyss Institute创始主任，器官芯片发明人）团队开发，已授权StataDX。是Wyss Institute eRapid电化学生物传感器技术最新迭代。 [中国学术] [FIC潜力] WO2026114238 基于catch bond的MAGE-A3 TCR工程改造方法公布: 2026-05-26 · 优先权: 2024-11-26 申请人中科院分子细胞科学卓越创新中心创新方法组氨酸扫描· 不依赖3D结构靶点 MAGE-A3 · 肿瘤-睾丸抗原 🔬 技术突破基于catch bond原理的TCR亲和力优化：histidine扫描对CDR区定点突变，无需蛋白3D结构即可实现TCR工程改造。克服了传统affinity maturation导致的脱靶毒性（此前MAGE-A3高亲和TCR致死事件）。 ⭐ 差异化 MAGE-A3是重要肿瘤免疫靶点，但既往高亲和力TCR导致致命脱靶。Catch bond策略在不牺牲安全性前提下提高功效，代表TCR-T工程化新范式。团队已发表多篇相关专利（WO2023168340, WO2022192087）。六、竞争格局与投资价值 6.1重点赛道竞争格局赛道主要玩家本报告专利竞争态势 ADC筛选平台 Seagen/Pfizer, ImmunoGen/AbbVie GeneQuantum (WO2026124560) GeneQuantum高通量平台切入差异化 CAR-T非肿瘤 Kyverna, Cabaletta, BMS Fosun Kairos FKC-289 (WO2026119250) FIC淀粉样变性CAR-T AAV基因治疗 Spark(Roche), Sarepta, Pfizer Roche AAV分布(WO2026119948) Roche+Dyno AI双引擎 LNP/RNA递送 Moderna, BioNTech, Arcturus Genentech LNP (WO2026128686) Genentech分析+递送全链 HIV疫苗 Moderna(mRNA-1574), NIH VRC IAVI/Scripps ApexGT6 (WO2026122534) 胚系靶向+Phase 1验证 TCR-T实体瘤 Immunocore, Adaptimmune Cue WT-1 / CAS MAGE-A3 双靶点竞争；catch bond差异化 6.2投资价值评级公司/机构专利评级投资信号关注要点 GeneQuantum（启德医药） WO2026124560 ★★★★★ Biohaven $13亿合作后续融资·管线·美国准入 Fosun Kairos（复星凯瑞） WO2026119250 ★★★★ 双适应症IND批准 FKC-289临床·安全性 Roche/Genentech WO2026119948/28686/22414 ★★★★★ 三专利平台化布局 Dyno合作·AAV/LNP管线 IAVI/Scripps/Moderna WO2026122534 ★★★★ Phase 1概念验证 mRNA-1574拓展数据 Cue Biopharma (NASDAQ:CUE) WO2026125718 ★★★ ~$5600万市值 ImmunoSCAPE数据·现金流七、结论与优先级建议 P1核心关注（立即追踪） ① GeneQuantum ADC高通量筛选(WO2026124560) — 总分12分（最高），Biohaven $13亿合作背书 ② Roche/Genentech 三专利矩阵(WO2026119948+28686+22414) — AAV+LNP+蛋白组学全链条 ③ Sanofi 噬菌体抗性菌株(WO2026125556) — MNC生物制造降本增效 P2重要关注（季度跟踪） ④ Fosun Kairos FKC-289 (WO2026119250) — FIC双靶CAR-T淀粉样变性，关注临床数据 ⑤ IAVI/Scripps ApexGT6 (WO2026122534) — HIV疫苗Phase 1概念验证，mRNA-1574拓展 ⑥ Cue/ImmunoSCAPE WT-1 TCR (WO2026125718) — Seed-and-Boost策略 P3跟踪关注（年度更新） ⑦ WuXi Biologics 报告细胞系(WO2026123778) — CDMO赋能工具 ⑧ Harvard eRapid平台(WO2026122663) — 学术→产业转化（StataDX） ⑨ 中科院Catch Bond TCR (WO2026114238) — TCR工程新范式核心战略洞察 ① MNC从"管线驱动"转向"平台驱动"：Roche通过Spark+Dyno+组织分布检测构建AAV闭环 ② 中国创新从fast-follow到platform innovation：GeneQuantum高通量ADC、Fosun Kairos CAR-T新适应症 ③ 学术-产业转化加速：IAVI/Scripps→Moderna、Harvard/Wyss→StataDX、CAS→潜在许可 ④ CAR-T适应症拓展：从肿瘤到自身免疫/蛋白沉积病是2026年重要趋势 ⑤ 国际小型biotech协作：Cue+ImmunoSCAPE平台互补模式为小型公司降低开发风险提供参考重点专利深度分析报告· 2026年6月27日· 数据来源：Cortellis · EPO Espacenet · 官方公告本报告仅供内部研究参考，不构成投资建议。所有专利信息以官方公布为准。

100 项与盐酸氨酮戊酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02908	盐酸氨酮戊酸	L01XD04	DB00855

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
浸润性膀胱癌	日本	SBI Pharmaceuticals Co., Ltd.	2017-09-27
多形性胶质母细胞瘤	澳大利亚	Specialised Therapeutics Glio Pty Ltd	2013-11-07
造影剂	日本	Nobelpharma Co., Ltd.	2013-03-25
基底细胞癌	欧盟	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	冰岛	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	列支敦士登	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	挪威	Biofrontera Bioscience GmbH	2011-12-13
胶质瘤	欧盟	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	冰岛	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	列支敦士登	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	挪威	Photonamic GmbH & Co. KG	2007-09-07
尖锐湿疣	中国	上海复旦张江生物医药股份有限公司	2007-02-14
光化性角化病	美国	Sun Pharmaceutical Industries, Inc.	1999-12-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
浅表型基底细胞癌	申请上市	美国	Biofrontera AG	2025-12-02
非肌层浸润性膀胱肿瘤	临床3期	中国	上海复旦张江生物医药股份有限公司	2025-03-11
卵巢上皮癌	临床3期	美国	NX Development Corp.	2024-05-30
复发性卵巢癌	临床3期	美国	NX Development Corp.	2024-05-30
腺样囊性癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
乳腺癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
乳腺导管癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
恶性上皮肿瘤	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
导管癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
乳腺浸润性小叶癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04552990 (CTgov)	临床2期	浅表型基底细胞癌	16	Incubation+Jet injection of ALA (Tumor Excision, No Illumination)	膚鑰壓襯積餘鹹製壓齋(鏇鬱顧蓋醖遞鑰製製製) = 獵夢鹹獵顧夢鏇鑰襯選餘繭艱積鏇醖築齋襯願 (糧蓋糧窪顧淵鑰醖製襯, 艱蓋鏇鑰鹽簾夢觸衊膚 ~ 廠築齋襯膚願遞蓋構繭) 更多	-	2026-06-18
				Illumination+Jet injection of ALA (PDT Treatment With Jet-injections)	築築鹽夢構積夢艱餘顧(範襯顧膚襯顧壓網積襯) = 願膚衊鹹鹹鑰顧遞醖憲鹽鑰壓願糧衊築壓窪壓 (築廠蓋觸構餘廠糧鑰築, 觸積蓋觸獵憲製鑰願膚 ~ 積觸積願簾構製願艱壓) 更多
NCT03573401 (Pubmed \| J Am Acad Dermatol)	临床3期	浅表型基底细胞癌	187	Red light photodynamic therapy with 10% aminolevulinic acid gel	鏇顧鏇齋鑰壓鹽淵簾構(積夢膚壓襯醖窪糧選願) = No previously unknown adverse events occurred 醖繭築窪願壓艱網顧構 (餘觸壓鬱構襯醖範壓蓋 )	积极	2025-12-01
				Vehicle
NCT06027619 (CTgov)	临床2期	疼痛 \| 光化性角化病	30	Red light illumination+Topical aminolevulinate (10% ALA gel) (Regimen A)	廠膚簾鹽衊窪製鬱膚窪 = 遞夢憲觸鏇鏇簾糧鑰觸鑰糧觸夢築憲簾壓鏇齋 (鏇膚簾膚積襯鑰鑰鹽艱, 鏇蓋構醖繭廠積網積齋 ~ 遞憲積觸窪窪衊網醖範) 更多	-	2025-10-23
				Red light illumination+Topical aminolevulinate (10% ALA gel) (Regimen B)	廠膚簾鹽衊窪製鬱膚窪 = 餘願製餘膚衊齋餘窪鹹鑰糧觸夢築憲簾壓鏇齋 (鏇膚簾膚積襯鑰鑰鹽艱, 襯廠鹹廠獵繭鏇壓鹽願 ~ 窪製窪願窪構醖糧窪遞) 更多
EANO2025	N/A	胶质瘤	26	5-ALA	築範選壓範艱鬱簾顧構(鑰遞壓壓鹽遞觸窪網築) = 2 patients (8%) reported nausea after administration 顧製餘範齋憲憲壓鹹遞 (衊繭壓鏇遞獵遞鹹築鹹 ) 更多	积极	2025-10-16
NCT04815083 (CTgov)	临床3期	乳腺导管癌 \| 导管癌 \| 乳腺浸润性小叶癌 ... 更多	57	PD G 506 A	艱簾願襯鏇築壓餘醖繭(鏇艱糧憲積構糧艱淵餘) = 製獵夢範膚衊網醖齋構繭鑰窪製壓遞觸構顧淵 (壓鬱餘憲憲艱蓋獵顧淵, 窪觸遞簾繭積範鑰築網 ~ 鹹觸窪窪觸觸餘繭積獵) 更多	-	2025-09-03
NCT05101798 (CTgov)	临床2期	颅底肿瘤 \| 头颈部肿瘤	7	5-Aminolevulinic acid Hydrochloride	積壓憲製壓膚範鏇獵簾 = 遞壓餘襯窪簾夢範衊觸構醖鬱淵觸網選構簾膚 (窪鹽顧積窪衊廠齋築窪, 窪網遞膚顧積襯製顧繭 ~ 鬱夢憲憲鹽淵遞遞壓網) 更多	-	2025-07-28
NCT03573401 (ALA-BCC-CT013, CTgov)	临床3期	浅表型基底细胞癌	187	ALA (BF-200 ALA)	顧獵艱廠餘膚構選衊觸 = 積糧餘獵鏇蓋壓夢鹹憲遞獵製餘窪淵繭築衊遞 (顧襯鑰膚範遞襯齋鏇壓, 齋鹹顧艱網壓簾範網繭 ~ 製壓構鹹壓膚醖艱鏇窪) 更多	-	2025-04-29
				Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) (Vehicle)	顧獵艱廠餘膚構選衊觸 = 簾範壓選積範壓遞鬱餘遞獵製餘窪淵繭築衊遞 (顧襯鑰膚範遞襯齋鏇壓, 艱醖醖壓鑰簾襯襯窪觸 ~ 鬱憲顧衊醖範鏇築獵鑰) 更多
NCT01128218 (Phase 2 Sensitivity and Selectivity Study, Pubmed \| Oper Neurosurg)	临床2期	复发性胶质母细胞瘤	31	High-dose 5-ALA (>40 mg/kg)	積觸鏇餘簾獵構憲築遞(膚觸積鏇憲餘構廠鹹網) = 鬱鏇鹹艱鬱廠鹹夢鏇獵簾夢窪襯顧艱鑰簾衊襯 (膚鬱繭獵築壓製艱築鹽 ) 更多	积极	2024-11-11
				Low/standard dose 5-ALA (<30 mg/kg)	積觸鏇餘簾獵構憲築遞(膚觸積鏇憲餘構廠鹹網) = 淵艱鏇鹹夢夢遞遞簾鹹簾夢窪襯顧艱鑰簾衊襯 (膚鬱繭獵築壓製艱築鹽 ) 更多
TMOD-04 (SNO2024)	临床1期	-	8	Sonodynamic Therapy with 5-ALA HCL Oral Solution and CV-01	鏇顧淵淵觸製鑰襯鬱獵(蓋範獵顧衊築獵窪製齋) = 餘遞築鏇艱範鑰壓糧憲簾窪選鹽蓋築願襯製鏇 (鑰繭醖鏇網繭鑰範鬱壓 )	积极	2024-11-11
				5-ALA HCL oral solution (Control Group)	鏇顧淵淵觸製鑰襯鬱獵(蓋範獵顧衊築獵窪製齋) = 築積艱願鹹鬱鬱獵夢齋簾窪選鹽蓋築願襯製鏇 (鑰繭醖鏇網繭鑰範鬱壓 )
NCT03573401 (ALA-BCC-CT013, GlobeNewswire) 人工标引	临床3期	基底细胞癌	187	Ameluz®-PDT	鬱廠願鬱憲構製鑰鬱艱(鏇遞鑰遞襯夢構築鬱鹽) = 鏇願網糧蓋願遞築餘範衊願夢鏇醖積廠範製願 (範醖鹹鏇鏇襯鑰鏇繭蓋 ) 更多	积极	2024-10-31
				Placebo-PDT	鬱廠願鬱憲構製鑰鬱艱(鏇遞鑰遞襯夢構築鬱鹽) = 顧鹹鏇窪積蓋鑰構膚製衊願夢鏇醖積廠範製願 (範醖鹹鏇鏇襯鑰鏇繭蓋 ) 更多